Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.

3825529

Reuters

United Kingdom

WHO approves Bavarian Nordic's mpox vaccine for adolescents

WHO approves Bavarian Nordic's Jynneos vaccine for adolescents aged 12-17 to combat global mpox outbreak.

Media Bias/Fact Check

The Hindu

The Hindu Group

India

WHO approves Bavarian Nordic’s mpox vaccine for adolescents

Ad Fontes Media

All Sides

The Woodbridge Company

The WHO said Friday it had for the first time prequalified a mpox vaccine -- a move expected to speed up access to the jabs to fight an epidemic raging in Africa. The announcement came on the heels of the arrival of the first MVA-BN vaccines to the Democratic Republic of Congo (DRC), the epicentre of the epidemic. "This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of …

NDTV

Independent Media

Gautam Adani

New Delhi

Delhi Division

Delhi

WHO Adds First Mpox Vaccine To Its List, Expected To Speed Up Distribution

European agency also allowed the age range to be expanded; immunizer has exceptional authorization for adults in Brazil. The World Health Organization (WHO) has approved the expansion of the vaccine from the Danish manufacturer Bavarian Nordic against mpox, called Jynenos or Imvanex, to adolescents aged 12 to 17. In September, the dose was the first to be approved by the agency for people over 18 years of age.
The decision to update the age rang…

Agência europeia também permitiu a ampliação da faixa etária; imunizante tem autorização excepcional para adultos no Brasil A Organização Mundial da Saúde (OMS) aprovou a ampliação da vacina da fabricante dinamarquesa Bavarian Nordic contra a mpox, chamada de Jynneos ou Imvanex, para adolescentes de 12 a 17 anos. Em setembro, a dose foi a primeira a receber o aval do órgão para maiores de 18 anos.
A decisão de atualizar a faixa etária foi tomada…

OMS aprova vacina contra mpox para adolescentes de 12 a 17 anos

Globo

Roberto Irineu Marinho

Brazil

WHO approves mpox vaccine for adolescents aged 12 to 17

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern. Read more at straitstimes.com.

The Straits Times

Singapore Press Holdings

Singapore

Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 has been approved, WHO announced.

The West Australian

Kerry Stokes

Australia

WHO approves mpox vaccine for adolescents

GENEVA: The World Health Organization said on Monday it had approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern. The WHO said it gave the Jynneos vaccine prequalification for adolescents on Oct. 8. The organization declared mpox a global public

Arab News

Saudi Research and Marketing Group

Riyadh

Riyadh Province

Saudi Arabia

People aged 12 to 17 are considered particularly vulnerable to outbreaks of monkeypox.

Людей в возрасте от 12 до 17 лет считают особенно уязвимыми к вспышкам обезьяньей оспы.

ВОЗ одобрила вакцину от оспы обезьян для подростков

Korrespondent.net

Kyiv

Kyiv City Municipality

Kyiv City Region

Ukraine

WHO approves monkeypox vaccine for teenagers

PerthNow

City of Perth

Western Australia

The World Health Organization announced on Monday, October 14, that it has approved the Bavarian Nordic smallpox vaccine for adolescents between the ages of 12 and 17, an age group considered particularly vulnerable to outbreaks of the disease that have sparked global concern.

Organizația Mondială a Sănătății a anunțat luni, 14 octombrie, că a aprobat vaccinul anti-mpox Bavarian Nordic, pentru adolescenții cu vârste cuprinse între 12 și 17 ani, o grupă de vârstă considerată deosebit de vulnerabilă la focarele bolii care a declanșat o îngrijorare globală.

OMS a aprobat un vaccin anti-mpox, boală cunoscută drept „Variola maimuței”. Poate fi utilizat la adolescenţii cu vârste între 12 şi 17 ani

Adevarul

Romania

The WHO has approved a vaccine against mpox, the disease known as "Monkey Pox". It can be used in adolescents aged between 12 and 17 years

WHO approves Bavarian Nordic's mpox vaccine for adolescents

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics